Moxonidine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Moxonidine: From Hypertension to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
Moxonidine is a centrally-acting antihypertensive — a selective imidazoline I1-receptor agonist used to treat essential hypertension (per the repurposing rationale in this evidence pack; formal indication data is not recorded separately). The TxGNN model’s top-ranked prediction is Hypotrichosis Simplex of the Scalp, a hereditary hair-follicle disorder, with a prediction score of 99.95%. However, there are 0 clinical trials and 0 publications supporting this specific prediction, and the evidence pack itself notes no known mechanistic link — this is a model-score-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in formal registration data (drug not marketed in Australia); referenced as hypertension in the prediction rationale narrative |
| Predicted New Indication | Hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action (MOA) data is not available for moxonidine (flagged as a data gap in this evidence pack). Based on the narrative accompanying other candidate predictions in this pack, moxonidine is described as a selective imidazoline I1-receptor agonist acting on the rostral ventrolateral medulla (RVLM) to suppress sympathetic outflow, and is used clinically to lower blood pressure in essential hypertension.
Hypotrichosis simplex of the scalp is a hereditary disorder of hair-follicle development, unrelated to blood pressure regulation. The evidence pack’s own assessment for this prediction states explicitly that there is no known mechanistic link between moxonidine’s sympatholytic, antihypertensive action and this condition. No clinical trials or literature were found connecting the two.
In short, this is a high-scoring but mechanistically unsupported model output — the score reflects a pattern learned by TxGNN across the knowledge graph, not a validated biological hypothesis. Readers should treat this as a candidate for further research screening only, not as a signal with independent clinical or scientific corroboration.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Australia Market Information
Moxonidine has no ARTG entries and is not currently marketed in Australia (0 licenses on record in this evidence pack).
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
(Note: this evidence pack flags TGA/PI warning and contraindication data as a blocking data gap — DG001 — so safety cannot be independently assessed from the data provided here.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (hypotrichosis simplex of the scalp) has no supporting clinical trials, no literature, and no plausible mechanistic link per the pack’s own assessment — it is an L5, model-score-only signal (rank 1108 among all TxGNN predictions for this drug).
To proceed, the following is needed:
- Moxonidine’s mechanism of action (MOA) data (DG002, High severity)
- TGA-approved Product Information — warnings and contraindications (DG001, Blocking severity)
- Independent mechanistic or preclinical rationale connecting moxonidine to hair-follicle biology before this candidate can move beyond S0
Note for reviewers: this evidence pack also contains lower-scoring but more mechanistically coherent candidates for moxonidine — e.g. malignant hypertensive renal disease, malignant renovascular hypertension, and primary hereditary glaucoma (all L4, S1, “Research Question”) — where the rationale draws on plausible class-effect or downstream-pathology reasoning, though these likewise lack direct trials or literature. If the goal is identifying a scientifically defensible repurposing hypothesis rather than the single highest TxGNN score, those candidates may warrant separate evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.